Health Catalyst shares are trading lower after the company reported Q4 financial results and issued Q1 and FY24 revenue guidance below estimates. Also, Canaccord Genuity maintained a Buy rating on the stock but lowered its price target from $12 to $11.
Benzinga Newsdesk - Feb 23, 2024, 12:01PM